Outcome Measures
PD
BLOOD, DRUG EFFECT
A subjective drug effect questionnaire was administered, and vitals and blood were sampled at baseline and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after CYP cocktail administration. A battery of PD assessments was completed at baseline and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours after CYP cocktail administration during each session.Blood was collected into 10-mL ethylenediaminetetraacetic acid-containing vacutainer tubes and spun at 1200 g at 4 °C for 10 minutes to obtain plasma. Plasma was stored at −80 °C and shipped frozen on dry ice to the Unadkat laboratory at the University of Washington for analysis of Δ9-THC, CBD, CYP probe drugs, and corresponding metabolites. Concentrations of Δ9-THC, 11-OH-Δ9-THC, and Δ9-THC-COOH were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) after employing a liquid-liquid extraction process.Subjective drug effects were assessed with the Drug Effect Questionnaire (DEQ), which has established sensitivity to the acute effects of THC and cannabis.Cognitive and psychomotor performance was assessed using 3 computerized tasks that have been shown to be sensitive to acute effects of THC and cannabis